It has been demonstrated that aldosterone impairs InsR signaling by inducing ROS production and altering the PI3K/Akt/eNOS pathway, therefore, mineralocorticoid receptor antagonists have been proposed as therapeutic tools to minimize vascular damage in DM2 (Bruder-Nascimento et al., 2014). Here, NOS3 is linked to myotonic dystrophy type 2.